-
Mashup Score: 26Financial Toxicity in Cancer Care: Where Are We, and How Did We Get Here? Introduction to a Special Series | JCO Oncology Practice - 13 hour(s) ago
The first academic article using the term “financial toxicity” was published in 2013, 1 which catalyzed the growth of an emerging field of research and quality improvement efforts focused on addressing patient affordability concerns. Although previous research had begun to describe the financial burden experienced by patients with cancer and the exorbitant costs of cancer care, the seminal article from Zafar et al and the subsequent editorials from experts we now recognize as leaders in this field
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 25
PURPOSENational Comprehensive Cancer Network Guidelines recommend initiating postoperative radiation therapy (PORT) within 6 weeks of surgery for patients with head and neck squamous cell carcinoma (HNSCC), but delays affect 50% of patients, …
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet-
Randomized Trial of Enhanced Versus Standard Navigation to Promote Timely Initiation of Adjuvant Radiotherapy for Head and Neck #Cancer. https://t.co/MwkzRyw6QM @ASCO @JCO_ASCO @JCOOP_ASCO #CancerResearch #SuppOnc #CancerCare @muschollings @MUSChealth https://t.co/DvXh3VhufA
-
-
Mashup Score: 18CT‐Based Body Composition and Frailty as Predictors of Survival Among Older Adults With Gastrointestinal Malignancies - 18 day(s) ago
Background Older adults with cancer are at an increased risk of treatment related toxicities and early death. Routinely collected clinico-demographic characteristics inadequately explain this increa…
Source: onlinelibrary.wiley.comCategories: General Medicine News, Hem/OncsTweet-
CT-Based Body Composition and Frailty as Predictors of Survival Among Older Adults With Gastrointestinal Malignancies. https://t.co/uxf2ZGS9lH @JCSM_cachexia @UAB_ICOS @GrantWilliamsMD #ColonCancer #PancreaticCancer #CancerResearch #GeriOnc #PallOnc https://t.co/hbo4CDJZbP
-
-
Mashup Score: 8Participation in the Acute Hospital Care at Home Program - 19 day(s) ago
This cross-sectional study explores whether hospital participation in the Acute Hospital Care at Home program continued to increase following the extension of the program and the characteristics of participating hospitals.
Source: jamanetwork.comCategories: General Medicine News, Hem/OncsTweet-
Hospital Participation in the Acute Hospital Care at Home Waiver Program. https://t.co/yIqnkIeLHJ @JAMA_current @JAMANetwork #HospitalAtHome https://t.co/GUSX4I7wYa
-
-
Mashup Score: 40
PURPOSEThe concept of time toxicity of cancer treatment, defined as proportion of days from physical contact with the health care system, has been suggested as simple, patient-centered measure useful for shared decision making, particularly in incurable …
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet-
Time Toxicity of Systemic Anticancer Therapy for Metastatic Lung #Cancer in Routine Clinical Practice: A Nationwide Cohort Study. https://t.co/hhjCSPR9ov @ASCO @JCO_ASCO @JCOOP_ASCO #CancerResearch #TimeToxicity #FinancialToxicity #CancerCare #LungCancer https://t.co/nP4J7vMnPi
-
-
Mashup Score: 25Impact of Financial Toxicity on Treatment Adherence and Quality of Life in Pancreatic Cancer | JCO Oncology Practice - 21 day(s) ago
PURPOSEFinancial toxicity (FT) is increasingly recognized as a major issue in cancer care. We evaluated the prevalence and risk factors for FT in patients with pancreatic ductal adenocarcinoma (PDAC) and FT associations with treatment adherence and …1 in 4 pancreatic cancer patients experiences financial toxicity, negatively impacting quality of life
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet-
Impact of Financial Toxicity on Treatment Adherence and Quality of Life in Pancreatic #Cancer. https://t.co/xiXXQn9FiP @ASCO @JCO_ASCO @JCOOP_ASCO #PancreaticCancer #FinancialToxicity #PallOnc @MSKCancerCenter https://t.co/H835V1OBjT
-
-
Mashup Score: 25Remote Symptom Monitoring of Patients With Advanced Lung Cancer (The ProWide Study): A Randomized Controlled Trial | JCO Oncology Practice - 29 day(s) ago
PURPOSERemote symptom monitoring of patients with cancer has previously shown potential for improving clinical outcomes. This study aimed to evaluate the effects of remote symptom monitoring in patients with lung cancer after palliative induction …
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet-
Remote Symptom Monitoring of Patients With Advanced Lung #Cancer (The ProWide Study): A Randomized Controlled Trial. https://t.co/vqNxbMjeW7 @ASCO @JCO_ASCO @JCOOP_ASCO #LungCancer #PallOnc #SuppOnc https://t.co/YL1hgcoEYr
-
-
Mashup Score: 27Qualitative Study of Health Care Team Perception of the Benefits and Limitations of Remote Symptom Monitoring | JCO Oncology Practice - 1 month(s) ago
PURPOSERemote symptom monitoring (RSM) using electronic patient-reported outcomes (ePROS) connects patients and health care teams between appointments. Patient-perceived benefits and drawbacks of RSM are well-known, but health care team members’ …
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet-
Qualitative Study of Health Care Team Perception of the Benefits and Limitations of Remote Symptom Monitoring. https://t.co/q73Jti5uZW @ASCO @JCO_ASCO @JCOOP_ASCO #PallOnc #GeriOnc #SuppOnc #CancerResearch @UAB_ICOS @ONealCancerUAB https://t.co/oHpFdP8lM5
-
-
Mashup Score: 24
Prices of anticancer medicines (including chemically synthesized medicines and biologics manufactured from living organisms) are a subject of concern, as they contribute to spending by health plans and patients. We describe prices and evaluate the impact of competition among 185 anticancer medicines, using IQVIA data from the period October 2014–February 2020. We calculated the price of each medicine, defined as volume-weighted wholesale costs net of prompt-pay discounts and gross of rebates, without and with inflation adjustment, and summarized them by patent status, formulation, and therapeutic class. We evaluated the relationship between prices and competition, using regression analyses. We also conducted event studies of the impact of generic entry on the prices of three medicines from distinct clinically relevant therapeutic classes. Over the course of the study period, medicine prices increased among brand-name products and decreased among generics and biosimilars. After exclusiv
Source: www.healthaffairs.orgCategories: General Medicine News, Hem/OncsTweet-
US Trends In Anticancer Medicine Pricing And The Impact Of Competition, 2014-20. https://t.co/injvqAk5wE @Health_Affairs @contirena1 #CancerResearch #FinancialToxicity #CostsOfCare @CostsofCare https://t.co/QdY7iBWAhh
-
-
Mashup Score: 24
Prices of anticancer medicines (including chemically synthesized medicines and biologics manufactured from living organisms) are a subject of concern, as they contribute to spending by health plans and patients. We describe prices and evaluate the impact of competition among 185 anticancer medicines, using IQVIA data from the period October 2014–February 2020. We calculated the price of each medicine, defined as volume-weighted wholesale costs net of prompt-pay discounts and gross of rebates, without and with inflation adjustment, and summarized them by patent status, formulation, and therapeutic class. We evaluated the relationship between prices and competition, using regression analyses. We also conducted event studies of the impact of generic entry on the prices of three medicines from distinct clinically relevant therapeutic classes. Over the course of the study period, medicine prices increased among brand-name products and decreased among generics and biosimilars. After exclusiv
Source: www.healthaffairs.orgCategories: General Medicine News, Hem/OncsTweet-
US Trends In Anticancer Medicine Pricing And The Impact Of Competition, 2014-20. https://t.co/injvqAk5wE @Health_Affairs @contirena1 #CancerResearch #FinancialToxicity #CostsOfCare @CostsofCare https://t.co/QdY7iBWAhh
-
Financial Toxicity in #Cancer Care: Where Are We, and How Did We Get Here? Introduction to a Special Series. https://t.co/yBjE56pPA7 @ASCO @JCO_ASCO @JCOOP_ASCO #FinancialToxicity #PallOnc #CostsOfCare #GeriOnc @fumikochino @EthicsdoctorP @yzafar @jamecancerdoc https://t.co/Fi6F1Czx8R